|
|
News Categories:
|
| |
Phase II arimoclomol - Treatment of ALSMarch 08, 2006
"We are already in a Phase II clinical trial with our lead small molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and a Phase I trial with our HIV vaccine," added Mr. Kriegsman. "We look forward to entering the clinic with drug candidates derived from our RNAi-based drug discovery program, which represents an
important step toward the development of next generation medicines that address the large, underserved obesity and type 2 diabetes markets."
|
